

**Doncaster Place and Bassetlaw Place**
Medicines Optimisation Bulletin**November 2025**

Useful hyperlinks for Medicines Optimisation To open Press control and click the link below

[South Yorkshire Central ICB Medicines Optimisation Website.](#)[MPD](#)South Yorkshire Medicines Optimisation Team SY MOT : syicb-sheffield.syicb.medsopt1@nhs.net**Hot off the Press**
Updated Guidance

- Clozapine Guideline for Primary Care [Click here](#)
- DOAC SY position statement [Click here](#)
- Children's & Young People's (CYP) asthma guidelines [Click here](#)
- Beclometasone dipropionate and formoterol fumarate dihydrate. ICS/LABA Proxor position Statement for new patients [Click here](#)

All documents are available on website and MPD

Important news on Rybelsus (oral semaglutide) and the introduction of the second-generation formulation

For information only : please await further advice from the MO team.

Update:

Future Action Plan when the new formulation is available on clinical systems:-

- **Patients currently taking Rybelsus** should be informed and advised about the change in formulation and dose when the new formulation is available on the clinical systems and will be prescribed and dispensed for the first time.
- **New patients starting Rybelsus** treatment should be prescribed the second-generation formulation and be suitably informed by the prescriber or pharmacist.

For more information

- Health professionals : Further information : [Document click here](#)
- Patient leaflet : further information : [Document click here](#)
- To contact the SYICB Medicines Optimisation Team, email : syicb-sheffield.syicb.medsopt1@nhs.net

Formulary updates November 2025The following items will be added/amended on the [MPD](#)

Formulary Section	Item	Indication	PMOC Action
9.1.1.1	Ferric maltol	Iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD) / Intermediate choice for mild to moderate iron deficiency prior to consideration of iron infusions	Approved as Green on SY TLS by IMOC but to remain Amber-G in Doncaster due to importance of patient selection, but GPs with special interest in this treatment could prescribe if appropriate to do so.
1.5.1	Mesalazine 1g suppositories	Mild-moderate active ulcerative colitis and for maintenance of remission	Octasa brand to be 1 st line choice in Primary care. Pentasa brand 2 nd line.
3.2	Beclometasone dipropionate and formoterol fumarate dihydrate. ICS/LABA	Asthma (Current guidance under review and SY Guidance being developed)	For new patients: 100/6 & 200/6 Proxor Brand 1 st line Luforbec 2nd line Fostair brand 3 rd line
3.2	Beclometasone dipropionate and formoterol fumarate dihydrate. ICS/LABA	COPD	For new patients: 100/6 only Proxor Brand 1 st line Luforbec 2nd line Fostair brand 3 rd line
4.1.2	Buspirone	Anxiety / For short-term use only, delayed onset of action; greater risk of discontinuation due to side effects; efficacy is reduced in previous extensive use of benzodiazepines; may be useful where benzodiazepines not used before.	Green Non-formulary as per RDaSH Formulary. To be used only when all formulary choices have been tried where appropriate.
4.7.2	Oxycodone MR tablets	Pain relief (Opioid)	Oxylan Brand first choice but for patients with soya or peanut allergy prescribe Oxypro brand. Both products on MPD
	Mirabegron	Overactive bladder syndrome	Mirabegron should not be prescribed for patients age 17years and under.

Antibiotic duration reminder:**For most common infections, including respiratory tract infections, a 5-day course of amoxicillin or doxycycline is recommended. Longer courses are rarely needed and increase the risk of antimicrobial resistance.**